Thrombin drives tumorigenesis in colitis-associated colon cancer.
The established association between inflammatory bowel disease and colorectal cancer underscores the importance of inflammation in colon cancer development. On the basis of evidence that hemostatic proteases are powerful modifiers of both inflammatory pathologies and tumor biology, gene-targeted mice carrying low levels of prothrombin were used to directly test the hypothesis that prothrombin contributes to tumor development in colitis-associated colon cancer (CAC). Remarkably, imposing a modest 50% reduction in circulating prothrombin in fII+/- mice, a level that carries no significant bleeding risk, dramatically decreased adenoma formation following an azoxymethane/dextran sodium sulfate challenge. Similar results were obtained with pharmacologic inhibition of prothrombin expression or inhibition of thrombin proteolytic activity. Detailed longitudinal analyses showed that the role of thrombin in tumor development in CAC was temporally associated with the antecedent inflammatory colitis. However, direct studies of the antecedent colitis showed that mice carrying half-normal prothrombin levels were comparable to control mice in mucosal damage, inflammatory cell infiltration, and associated local cytokine levels. These results suggest that thrombin supports early events coupled to inflammation-mediated tumorigenesis in CAC that are distinct from overall inflammation-induced tissue damage and inflammatory cell trafficking. That prothrombin is linked to early events in CAC was strongly inferred by the observation that prothrombin deficiency dramatically reduced the formation of very early, precancerous aberrant crypt foci. Given the importance of inflammation in the development of colon cancer, these studies suggest that therapeutic interventions at the level of hemostatic factors may be an effective means to prevent and/or impede colitis-associated colon cancer progression.
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Brian
B
Turpin
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Whitney
W
Miller
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Leah
L
Rosenfeldt
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Keith
K
Kombrinck
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Matthew J
MJ
Flick
Divisions of Gastroenterology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Kris A
KA
Steinbrecher
Divisions of Gastroenterology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Eleana
E
Harmel-Laws
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Eric S
ES
Mullins
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Maureen
M
Shaw
Pathology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
David P
DP
Witte
Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Alexey
A
Revenko
Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Brett
B
Monia
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, and ISIS Pharmaceuticals, Carlsbad CA.
Joseph S
JS
Palumbo
D000236:Adenoma / Q000378:metabolism / Q000473:pathology; D000818:Animals; D063646:Carcinogenesis / Q000378:metabolism; D002273:Carcinogens / Q000378:metabolism; D003092:Colitis / Q000378:metabolism* / Q000473:pathology*; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D016207:Cytokines / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011516:Prothrombin / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism*
D002273:Carcinogens; D016207:Cytokines; D011516:Prothrombin; D013917:Thrombin